Brokers Offer Predictions for VKTX Q1 Earnings

Viking Therapeutics, Inc. (NASDAQ:VKTX) – Equities research analysts at HC Wainwright issued their Q1 2026 earnings estimates for Viking Therapeutics in a research report issued to clients and investors on Thursday, February 12th. HC Wainwright analyst J. Pantginis expects that the biotechnology company will earn ($0.58) per share for the quarter. The consensus estimate for Viking Therapeutics’ current full-year earnings is ($1.56) per share. HC Wainwright also issued estimates for Viking Therapeutics’ Q2 2026 earnings at ($0.64) EPS, Q3 2026 earnings at ($0.72) EPS and FY2026 earnings at ($2.75) EPS.

Viking Therapeutics (NASDAQ:VKTX) last posted its quarterly earnings data on Wednesday, February 11th. The biotechnology company reported ($1.38) EPS for the quarter, missing analysts’ consensus estimates of ($0.89) by ($0.49). During the same period last year, the company posted ($0.32) earnings per share.

VKTX has been the subject of several other reports. Canaccord Genuity Group increased their price objective on Viking Therapeutics from $106.00 to $107.00 and gave the company a “buy” rating in a research report on Wednesday, November 12th. B. Riley Financial raised shares of Viking Therapeutics to a “strong-buy” rating in a report on Thursday, October 23rd. Morgan Stanley restated an “overweight” rating and issued a $99.00 price target on shares of Viking Therapeutics in a research report on Thursday, February 12th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Viking Therapeutics in a research report on Wednesday, January 21st. Finally, JPMorgan Chase & Co. reduced their target price on shares of Viking Therapeutics from $80.00 to $75.00 and set an “overweight” rating for the company in a research note on Friday, October 24th. Three analysts have rated the stock with a Strong Buy rating, six have given a Buy rating, two have issued a Hold rating and two have assigned a Sell rating to the stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $87.80.

Viking Therapeutics Stock Up 5.0%

VKTX opened at $30.45 on Monday. The stock’s 50 day moving average price is $32.82 and its two-hundred day moving average price is $32.53. The firm has a market capitalization of $3.52 billion, a P/E ratio of -9.58 and a beta of 0.75. Viking Therapeutics has a 12-month low of $18.92 and a 12-month high of $43.15.

Institutional Investors Weigh In On Viking Therapeutics

Several large investors have recently made changes to their positions in VKTX. Jump Financial LLC bought a new position in Viking Therapeutics during the 2nd quarter worth $12,201,000. Norges Bank acquired a new position in shares of Viking Therapeutics during the 2nd quarter worth approximately $46,846,000. RFG Advisory LLC raised its position in shares of Viking Therapeutics by 84.8% in the third quarter. RFG Advisory LLC now owns 120,214 shares of the biotechnology company’s stock valued at $3,159,000 after buying an additional 55,175 shares in the last quarter. Marex Group plc bought a new stake in shares of Viking Therapeutics in the second quarter valued at approximately $983,000. Finally, Bryce Point Capital LLC acquired a new stake in Viking Therapeutics during the second quarter worth approximately $499,000. Institutional investors own 76.03% of the company’s stock.

Insider Buying and Selling at Viking Therapeutics

In other news, COO Marianna Mancini sold 57,661 shares of the company’s stock in a transaction that occurred on Monday, January 5th. The stock was sold at an average price of $32.98, for a total value of $1,901,659.78. Following the sale, the chief operating officer directly owned 409,190 shares in the company, valued at approximately $13,495,086.20. This represents a 12.35% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, CEO Brian Lian sold 233,409 shares of the stock in a transaction on Monday, January 5th. The stock was sold at an average price of $32.96, for a total value of $7,693,160.64. Following the transaction, the chief executive officer owned 2,499,291 shares of the company’s stock, valued at $82,376,631.36. This represents a 8.54% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders sold 364,731 shares of company stock worth $12,053,627. 4.10% of the stock is currently owned by company insiders.

About Viking Therapeutics

Viking Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders. Headquartered in San Diego, California, the company’s pipeline leverages small-molecule approaches to target hormone signaling pathways implicated in conditions such as non‐alcoholic steatohepatitis (NASH), dyslipidemia, type 2 diabetes and muscle wasting disorders.

The company’s lead programs include VK2809, a thyroid hormone receptor‐beta agonist designed to reduce liver fat and improve lipid profiles in patients with NASH and dyslipidemia, and VK5211, a selective androgen receptor modulator (SARM) aimed at enhancing muscle mass and function in individuals with muscle wasting conditions.